1. In Vivo
  2. >>Deal-Making

Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles

 
• By David Wild

In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.

Nimbus Therapeutics Closed One of the Largest Single-Asset Deals in Biotech History • Source: Shutterstock

In December 2022, Nimbus Therapeutics, Inc. signed a near record-setting $4bn single-asset deal with Takeda Pharmaceutical Co. Ltd., providing the Japanese pharma with its highly selective allosteric Tyrosine kinase 2 (TYK2) inhibitor, now called TAK-279, and the portfolio of intellectual property around the program. (Also see "Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor" - Scrip, 13 December, 2022.)

The sale was finalized after the agent, formerly known as NDI-034858, significantly bested placebo according to topline results of a...

More from Deal-Making

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.